| __timestamp | Amneal Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 612613000000 |
| Thursday, January 1, 2015 | 109679000 | 650773000000 |
| Friday, January 1, 2016 | 118757000 | 619061000000 |
| Sunday, January 1, 2017 | 109046000 | 628106000000 |
| Monday, January 1, 2018 | 230435000 | 717599000000 |
| Tuesday, January 1, 2019 | 289598000 | 964737000000 |
| Wednesday, January 1, 2020 | 326727000 | 875663000000 |
| Friday, January 1, 2021 | 365504000 | 886361000000 |
| Saturday, January 1, 2022 | 399700000 | 997309000000 |
| Sunday, January 1, 2023 | 429675000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc. present a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, Takeda's SG&A expenses have shown a steady upward trend, peaking at approximately 1.05 trillion yen in 2023, reflecting a robust 72% increase since 2014. This growth underscores Takeda's expansive global operations and strategic investments.
Conversely, Amneal Pharmaceuticals, Inc. has experienced a more modest rise in SG&A expenses, with a 408% increase from 2014 to 2023, reaching around 430 million dollars. This indicates a more conservative approach, likely focusing on cost efficiency and targeted market expansion. The data for 2024 is incomplete, suggesting ongoing developments in these companies' financial strategies.
Takeda Pharmaceutical Company Limited vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Insmed Incorporated
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Pharming Group N.V.
Who Generates More Revenue? Takeda Pharmaceutical Company Limited or Amneal Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Perrigo Company plc
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Galapagos NV
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs ImmunityBio, Inc.